COURT-RULING filed Apr 7, 2026 at 20:00 ET
In the Zostavax MDL pending in the Eastern District of Pennsylvania, Judge Bartle granted Merck's motion to dismiss with prejudice 295 product-liability cases for failure to comply with discovery deadlines (PTO 526). Over the course of the eight-year MDL, no plaintiff had ever produced admissible expert testimony supporting causation. This ruling permanently terminates nearly all remaining case inventory from the Zostavax litigation and removes a long-tail contingent liability for Merck.